Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > COMMENTARY
COMMENTARY
- How Will Industry Counter Proposed Re-Pricing of “Huge Seller” Drugs?
August 18, 2015
- Leaner Sales Forces? Lower Profits? Drug Makers Face Tough Decision in 80% Generic Era
August 14, 2015
- PMDA Poised to Tap Big Data to Refine Reviews, Safety Steps; Dedicated Center Eyed in 2018
August 12, 2015
- Wholesalers Face Pressing Need to Retool Biz Strategy as Generics Gain Ground
July 21, 2015
- Viable Third-Party Review System Required for Drug Makers’ Advertisements
July 7, 2015
- Japan Compassionate Use System a “Stick” for Drug Makers? Incentives to Counter Their Burden Needed
June 22, 2015
- Generic Makers Baffled by New Govt Target, Quality and Supply Concerns Linger
June 15, 2015
- Thorny Path Ahead toward Trial Rollout of Cost-Effective Assessment in FY2016; Chuikyo to Begin Discussions on May 27
May 26, 2015
- 1 Year after Viagra Generic Debut, Freely Priced Generics Seem to Be Bringing Benefits
May 8, 2015
- Opdivo Offers Hope but Poses Challenges Too, Cautious Approach Needed to Expand Indications
April 27, 2015
- Will Japanese Drug Makers Become More Discerning in Unearthing Seeds?
April 17, 2015
- Patient Subsidy System Expanded for Intractable Diseases, What about Incentives for Drug Makers?
April 7, 2015
- Abe Pledges Biosimilar Promotion, but Doctor Misconception and Lack of Incentives Remain as Challenges
March 30, 2015
- SGLT-2 Inhibitor Sales Would Plunge If Used Only in Younger, Obese Patients, but Cautious Administration Warranted
March 17, 2015
- Uncertainty Swirling around Possible Drug Price Cuts for 3 Straight Years
March 16, 2015
- Drug Repositioning May Promise Greater Chance of Success, but Problems Remain
March 6, 2015
- As Adjuvant Development Race Heats Up, New Databases Could Turn Japan into Global Vaccine Powerhouse
February 16, 2015
- Japan Poised to Tap Its Version of “Compassionate Use” to Combat Challenges Left for Unapproved Drugs
February 2, 2015
- Open Innovation Bandwagon Gathers Pace for Efficient Drug Discovery
January 26, 2015
- Have AGs Finally Become a Good Option to Counter Generics?
January 19, 2015
ページ
A doctor member of the Central Social Insurance Medical Council (Chuikyo) on September 20 traded barbs with pharma leaders over…
The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
IntroductionCommercial transformation is a top priority for pharma leaders in Japan and rightfully so. In a market with low single…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…